IPBronch.com | Interventional Pulmonology

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer Jul 30, 2026

Bridging evidence and practice: international multidisciplinary consensus on non-metastatic NSCLC.

Study Takeaway

Provides broader context on multidisciplinary management of NSCLC that impacts staging and biopsy referrals.

Meyer ML; Peters S; Borghaei H; Cascone T; Dacic S; Faivre-Finn C

IP Score: 6/10 View Analysis →

American journal of respiratory and critical care medicine Jul 27, 2026

Tool In Lesion- But Still Off Target: A Call of Concern for Lung Cancer Screening.

Study Takeaway

Highlights ongoing limitations in targeting peripheral pulmonary lesions during screening and bronchoscopy.

Schwartz J; Murn M; Laniado I; Studts JL; Bade BC

IP Score: 6/10 View Analysis →

Chest Jul 16, 2026

Evolving Lung Cancer Navigator Practice Through Targeted Professional Development: A Long-term Outcomes Analysis.

Study Takeaway

Highlights the importance of multidisciplinary coordination in the IP lung cancer diagnostic pathway.

Lloyd SJ; Mortman MF; Monahan PO; Slaven JE; Lemery C; Podsiad M

IP Score: 6/10 View Analysis →

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer Jul 14, 2026

Comparison of circulating tumor DNA assays for molecular residual disease detection in non-small cell lung cancer.

Study Takeaway

Relevant to the diagnostic and monitoring pathway for lung cancer patients often managed by IP for biopsy and staging.

Cui Q; Zhang JT; Yin H; Zhang KP; Xu J; Xu FP

IP Score: 6/10 View Analysis →

Chest Jul 1, 2026

Lung Cancer Incidence and Mortality after Negative Low-Dose CT Screening Results.

Study Takeaway

Relevant for IP clinicians involved in lung cancer screening programs and the management of screen-detected nodules.

Liu H; Yan S; Liu P; Zhang C; Wang Q; Shen Q

IP Score: 6/10 View Analysis →

Thorax Jun 25, 2026

Comparative cost-effectiveness of screening for lung cancer using different risk scores and thresholds: the Yorkshire Lung Screening Trial.

Study Takeaway

Optimizing screening criteria will likely increase the volume of screen-detected nodules requiring IP diagnostic intervention.

Zhang Y; Hinde S; Marshall CS; Hancock N; Simmonds I; Soares M

IP Score: 6/10 View Analysis →

Thorax Jun 15, 2026

Multimodality curative-intent treatment in NSCLC: an unprecedented era of change 2017-2025.

Study Takeaway

IPs must stay updated on these systemic therapy shifts as they influence the timing and necessity of diagnostic and staging bronchoscopy in the multimodality care pathway.

Evison M; Ahmed T; Chitnis M; Ward R; Netto D; Cove-Smith L

IP Score: 6/10 View Analysis →

Chest May 29, 2026

Smoking-Related Comorbidities Detected Through Low-dose CT Lung Cancer Screening: Current Evidence and Future Directions.

Study Takeaway

Highlights the importance of multidisciplinary management for incidental findings detected during lung cancer screening, which often leads to IP referral for diagnostic biopsy.

Revel MP; Goo JM; Vliegenthart R; Silva M; Snoeckx A

IP Score: 7/10 View Analysis →

Chest May 18, 2026

Natural history, treatment, survival, and causes of mortality in patients with subsolid and ground-glass nodules.

Study Takeaway

Provides critical context for the decision-making process regarding when to pursue diagnostic bronchoscopy versus radiographic surveillance for indeterminate nodules.

Bader JM; Prince SR; de Santis W; Kane ER; Tanoue L; Bader AS

IP Score: 7/10 View Analysis →

American journal of respiratory and critical care medicine May 4, 2026

Toward Precision in Lung Cancer: Screening, Susceptibility, and Therapeutic Resistance.

Study Takeaway

Highlights the evolving landscape of lung cancer management, which informs the diagnostic and staging roles of interventional pulmonologists in the era of precision oncology.

Nana-Sinkam P

IP Score: 6/10 View Analysis →

Journal of thoracic oncology May 2, 2026

Emerging Targeted Therapies for HER2-mutant Non-Small Cell Lung Cancer.

Study Takeaway

Relevant for IP clinicians involved in the diagnostic workup and tissue acquisition for molecular profiling in lung cancer patients.

Del Rio B; Masini S; Cáceres-Galvis C; Torres-Jiménez J; Bote H; Zurera M

IP Score: 6/10 View Analysis →

Journal of thoracic oncology Apr 27, 2026

Integrating Histologic Descriptors into the Ninth Edition TNM Staging Improves Prognostic Stratification of Lung Adenocarcinoma.

Study Takeaway

Relevant for IP clinicians performing diagnostic biopsies and staging, as these histologic features are often identified on tissue samples obtained via bronchoscopy.

Abolfathi H; Maranda-Robitaille M; Lamaze FC; Kordahi M; Armero VS; Orain M

IP Score: 6/10 View Analysis →

Literature Archives